STOK vs BRVE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
STOK · Stoke Therapeutics$26.81 ▼ 0.45%
BRVE · Braveheart Bio$20.39 ▲ 5.81%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- STOK -16.0%
- BRVE -31.6%
Head to head
| Metric | STOK | BRVE |
|---|---|---|
| Price | $26.81 | $20.39 |
| Change today | ▼ 0.45% | ▲ 5.81% |
| Market cap | $1.75B | $1.83B |
| Return, 3 months | -17.0% | -25.9% |
| Return, year to date | -15.5% | – |
| Return, 1 year | -8.6% | – |
| P/E (TTM) | – | – |
| P/B | 5.0 | 3.7 |
| P/E percentile vs own 5y | 23rd | 4th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +5.9% | – |
| Net profit growth (YoY) | -92.0% | +55.2% |
| Gross margin | – | – |
| Operating margin | -913.2% | – |
| Net margin | -862.1% | – |
| Return on equity | -73.6% | -13.2% |
| Analyst target vs. price | +80.3% | +123.1% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 52 | 51 |
| 30-day volatility | 50.0% | 69.7% |
| Max drawdown, 1 year | -41.3% | -41.9% |
| Trend read | Leaning bullish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BRVE is the largest of the group by market value.
- STOK has been the calmest stock over the last 30 days.